These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37526844)

  • 21. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
    Goh CW; Kellathur SN; Ong LL; Wu X
    Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
    Couture LA; Carpenter MK
    Stem Cells Transl Med; 2015 Oct; 4(10):1097-100. PubMed ID: 26285658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.
    Moffit JS; Blanset DL; Lynch JL; MacLachlan TK; Meyer KE; Ponce R; Whiteley LO
    Hum Gene Ther; 2022 Nov; 33(21-22):1126-1141. PubMed ID: 35994386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
    Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
    Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
    Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
    Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harmonization of legislation and regulations to achieve food safety: US and Canada perspective.
    Keener L; Nicholson-Keener SM; Koutchma T
    J Sci Food Agric; 2014 Aug; 94(10):1947-53. PubMed ID: 23818402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical development strategies for novel gene therapeutic products.
    Pilaro AM; Serabian MA
    Toxicol Pathol; 1999; 27(1):4-7. PubMed ID: 10367665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
    Choi M; Han E; Lee S; Kim T; Shin W
    Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research.
    Martín PG; Martinez AR; Lara VG; Naveros BC
    Clin Exp Med; 2014 Feb; 14(1):25-33. PubMed ID: 23014774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
    Marti A
    Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of natural health products in Canada.
    Smith A; Jogalekar S; Gibson A
    J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of human gene therapy.
    Rubanyi GM
    Mol Aspects Med; 2001 Jun; 22(3):113-42. PubMed ID: 11470139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell and gene therapy products in Malaysia: a snapshot of the industry's current regulation preparedness.
    Loh EYX; Goh PS; Mannan AMM; Mohd Sani N; Ab Ghani A
    Cytotherapy; 2021 Dec; 23(12):1108-1113. PubMed ID: 34362651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.